Products, Systems and Opportunities in Heart Failure Management

Table of Contents

Executive Summary

Section 1: Introduction

• 1.1 Scope of report
• 1.2 Heart Failure Background
• 1.3 Clinical Background
  • 1.3.1 Description of Symptoms
  • 1.3.2 Treatment Guidelines Under Review
    • 1.3.2.1 New AHA/HFSA Guidelines Previewed at 2002 HFSA Scientific Meeting
    • 1.3.2.2 Heart Failure Specialist, Cardiologist, Primary Care--Impact of Specialist Care on Patient Performance Measures
  • 1.3.3 Statistics
    • 1.3.3.1 Incidence, prevalence
    • 1.3.3.2 Hospital discharges
    • 1.3.3.3 Hospital readmissions
  • 1.3.4 Heart Failure Programs
    • 1.3.4.1 CV Disease Management Companies
    • 1.3.4.2 Hospital Programs
    • 1.3.4.3 Home Care Programs
    • 1.3.4.4 Outpatient Center Programs
      • 1.3.4.4.1 Role of Primary Care, Family Practitioner
      • 1.3.4.4.2 Role of Cardiologist
      • 1.3.4.4.3 PharmD involvement
      • 1.3.4.4.4 Role of Other Physician specialty(ies)
      • 1.3.4.4.5 Role of CV disease management companies

Section 2: Heart Failure-Non-Clinical Issues

• 2.1 Costs and cost-related issues:
  • 2.1.1 Hospitalizations
    • 2.1.1.1 Lost revenues in hospitals due to implementation of a heart failure program which reduced readmissions
    • 2.1.1.2 Net income loss in hospitals due to emergent readmissions of heart failure patients under DRG 127
    • 2.1.1.3 Increase in hosptial revenues from ancillary procedures
    • 2.1.1.4 Effects of nationwide nursing shortage.
    • 2.1.1.5 Efforts underway to manage costs
    • 2.1.1.6 Role of advanced home monitoring in reduction of CHF-related admissions
    • 2.1.1.7 Efforts underway to improve care
    • 2.1.1.8 HFSA�fs efforts
    • 2.1.1.9 Achieving cardiac excellence project
    • 2.1.1.10 Communication and friction between the heart failure community and the primary care community
  • 2.1.2 Chronic care
  • 2.1.3 Reimbursement

Section 3: Methods in Managing Heart Failure

• 3.1 Products Currently in use
  • 3.1.1 Monitoring products
    • 3.1.1.1 CO2 rebreathing
    • 3.1.1.2 Heart catheterization
    • 3.1.1.3 Noninvasive hemodynamic monitoring
    • 3.1.1.4 Networked electronic questionnaires
    • 3.1.1.5 Call-in voice mail
    • 3.1.1.6 Weight scales
  • 3.1.2 Medical treatments
    • 3.1.2.1 Diuretics
    • 3.1.2.2 Inotropes
    • 3.1.2.3 Vasodilators
  • 3.1.3 Medical devices treatments
    • 3.1.3.1 Implantable Cardioverter Defibrillators (ICDs)
    • 3.1.3.2 Resynchronization Therapy
• 3.2 New Technologies in the Management and Treatment of Heart Failure

Section 4: Hemodynamic assessments in the Diagnostics, Management, Prevention and Monitoring of Heart Failure

• 4.1 The Role of Hemodynamics and Vascular Function Assessment in Prevention, Treatment and Management of Heart Failure
• 4.2 Current Products Methods/Products/Usage Trends
  • 4.2.1 CO2 Rebreathing
  • 4.2.2 Heart Catheterization
  • 4.2.3 Newer Hemodynamic Measurement Monitoring Methods/Products
    • 4.2.3.1 Ambulatory Blood Pressure Monitoring
    • 4.2.3.2 Impedance Cardiography
    • 4.2.3.3 Implantable Monitoring
    • 4.2.3.4 Noninvasive Measurements/Monitoring
    • 4.2.3.5 Lower-Extremity Bioimpedance
  • 4.2.4 Markets and Opportunities
  • 4.2.5 Products and Competition
  • 4.2.6 Market Forecast 2001-2006
  • 4.2.7 Company Profiles
    • 4.2.7.1 A&D Medical-LifeSource
    • 4.2.7.2 AtCor Medical
    • 4.2.7.3 CardioDynamics International Corporation
    • 4.2.7.4 CardioMEMS
    • 4.2.7.5 CVP Diagnostics
    • 4.2.7.6 Data Sciences International
    • 4.2.7.7 Hypertension Diagnostics, Inc.
    • 4.2.7.8 IEM Americas
    • 4.2.7.9 Medtronic, Inc.
    • 4.2.7.10 Pulse Metric, Inc.
    • 4.2.7.11 Remon Medical Technologies
    • 4.2.7.12 Rozinn Medical
    • 4.2.7.13 Spacelabs Medical division of Instrumentarium
    • 4.2.7.14 SORBA Medical Systems, Inc.
    • 4.2.7.15 SunTech Medical Instruments
    • 4.2.7.16 VivoMetrics, Inc.
    • 4.2.7.17 VSM MedTech Ltd.
    • 4.2.7.18 Wantagh Incorporated

Section 5 THE ROLES OF CARDIOVASCULAR DISEASE MANAGEMENT COMPANIES IN HEART FAILURE

• 5.1 The Evolution of Disease Management Programs
• 5.2 Current and Future Roles of DM in Heart Failure
  • 5.2.1 Guidelines
  • 5.2.2 Program Goals
  • 5.2.3 Company Involvement in Reduction of CHF-Related Hospital Admissions and Readmissions
  • 5.2.4 Assessment Tools Used in Home Monitoring of CHF Patients
    • 5.2.4.1 Call Centers
    • 5.2.4.2 Interactive Voice Response Systems
    • 5.2.4.3 Telemonitoring Devices
    • 5.2.4.4 Enabling Technologies for Home Monitoring of CHF Patients
  • 5.2.5 Review of Market Opportunities and Competition - Company Profiles
    • 5.2.5.1 Alere Medical
    • 5.2.5.2 American Healthways
    • 5.2.5.3 Cardiocom Multi-Disease Management
    • 5.2.5.4 CorSolutions Medical, Inc.
    • 5.2.5.5 CyberCare, Inc.
    • 5.2.5.6 Disease Management Association of America
    • 5.2.5.7 Disease Management Purchasing Consortium & Advisory Counsel
    • 5.2.5.8 Health Alert, Inc.
    • 5.2.5.9 Health Hero Network, Inc.
    • 5.2.5.10 HomMed, LLC
    • 5.2.5.11 I-trax, Inc.
    • 5.2.5.12 LifeMasters Supported SelfCare, Inc.
    • 5.2.5.13 Landacorp, Inc
    • 5.2.5.14 McKesson Health Solutions, LLC
    • 5.2.5.15 Philips Medical (Agilent /HP)
    • 5.2.5.16 Protocol Driven Healthcare, Inc.
    • 5.2.5.17 Qmed Interactive Heart Management

Section 6: APPENDICES

• 6.1 Company Listing-Cardiovascular Disease Management
• 6.2 Company Listing-Heart Failure Management and Treatment Product Manufacturers